GlassScriptPhysician profile
Dov S Linzer
NPI 1659312684
$3,212.39
in general payments reported to CMS, 2019-2025
24 companies · $243 in 2025
The $243 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $258 · 2021: $712 · 2022: $537 · 2023: $395 · 2024: $504 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $690.69 | 2019-2025 | |
| Amgen INC. | $576.08 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $311.12 | 2019-2025 | |
| Amarin Pharma, INC. | $215.97 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $205.28 | 2019-2022 | |
| Cvrx, INC. | $178.38 | 2024 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.35 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $141.03 | 2022-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $113.48 | 2021-2024 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $81.08 | 2019 | |
| Merck Sharp & Dohme LLC | $79.54 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $77.31 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $71.10 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $64.51 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $49.41 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $35.89 | 2019-2020 | |
| Heartflow, INC. | $29.32 | 2023 | Ffrct |
| Glaxosmithkline, LLC. | $26.68 | 2025 | Arexvy, Shingrix |
| Agepha Pharma Fz LLC | $23.80 | 2024 | Lodoco |
| Azurity Pharmaceuticals, INC. | $20.83 | 2023 | Edarbi |
| Sanofi-Aventis U.S. LLC | $20.54 | 2021 | |
| Allergan, INC. | $15.98 | 2019 | |
| Lilly USA, LLC | $14.11 | 2024 | Mounjaro |
| Boston Scientific Corporation | $11.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dov Linzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.